⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515007 | 1.00 | — | — | |
| SCHEMBL2568389 | 1.00 | — | — | |
| SCHEMBL1003464 | 0.86 | POLB (0.73) | — | |
| SCHEMBL37939 | 0.86 | POLB (0.73) | — | |
| SCHEMBL2876578 | 0.86 | POLB (0.73) | — | |
| SCHEMBL1857058 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL2679258 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL2904191 | 0.85 | L3MBTL1 (0.64) | — | |
| SCHEMBL23533074 | 0.83 | L3MBTL1 (0.62) | — | |
| SCHEMBL17395466 | 0.82 | POLB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430035-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 Pharma LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024085661-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4274833-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116848114-A | Tricyclic derivatives useful as PARP7 inhibitors | 北京加科思新药研发有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-8283345-B2 | Azetidine analogues of nucleosidase and phosphorylase inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-10-09 | — | — | US | disclosed |
| CN-102574825-A | Thiazoles as cannabinoid receptor ligands | ABBOTT LAB | 2012-07-11 | — | — | CN | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100168141-A1 | AZETIDINE ANALOGUES NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2010-07-01 | — | — | US | disclosed |
| EP-2150269-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | WASHINGTON UNIVERSITY IN ST. LOUIS | 2009-03-12 | — | — | US | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008139986-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC., (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-0792146-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997002028-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-01-23 | — | — | WO | disclosed |